For example, downregulating TRIM14 expression may enhance the antitumor effects of TMZ+CuCl2 co-treatment in gliomas, while avoiding TRIM14′s promotion of resistance through the maintenance of high ATP7A expression. Here, ATP7A is linked to central nervous system cancer.